The year is still young, but Fresenius Medical Care, for one, is already looking ahead to 2023.
A new collaboration between Elligo Health Research and WHYZE Health aims to simplify clinical trials in Europe by allowing patients and contract research organizations to more easily share information.
Moderna is prepping for life after COVID, and CEO Stéphane Bancel says he’s “never been as busy” as the company considers potential M&A opportunities.
Sporting autographed casts for months may one day become a thing of the past. The FDA has approved a noninvasive bone healing device designed to be worn after a fracture that uses ultrasound waves to help push the body to mend itself faster.
All Takeda is trying to do with its billions-of-dollars worth of licensing deals in gene therapy is cure rare disease. Simple, right?
Swiss biotechs saw record-breaking revenue and R&D investment in 2021, which the industry hopes will lead people to look beyond homegrown giants like Roche and Novartis.
Seemingly still dissatisfied with Philips’ handling of its ongoing respiratory device recall, the FDA is now considering taking further action to force the Dutch medtech to tighten up its response to the safety event.
Using simplified ECG data taken from an Apple Watch, researchers at the Mayo Clinic were able to use an artificial intelligence algorithm to spot people whose hearts may be having trouble pumping blood out to the rest of the body.
A tough call from the FDA has led Spero Therapeutics to become the latest in an ever-growing line of biotechs taking evasive action to stay afloat. The company will halt the commercialization of its late-stage urinary tract infection drug and lay off three-quarters of its staff.
Though mammograms are seen as the current “gold standard” for breast cancer diagnosis, ultrasounds can actually provide a more accurate image of the breast tissue in younger women and others with denser tissue in addition to offering a less expensive, radiation-free alternative to mammography.